Inhibrx Biosciences, Inc.
INBX
$82.96
$0.710.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.40M | 1.40M | 200.00K | 200.00K | 1.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.40M | 1.40M | 200.00K | 200.00K | 1.73M |
| Cost of Revenue | 146.95M | 157.30M | 202.67M | 229.64M | 252.47M |
| Gross Profit | -145.55M | -155.90M | -202.47M | -229.44M | -250.73M |
| SG&A Expenses | 49.62M | 52.25M | 139.19M | 143.14M | 119.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 196.57M | 209.55M | 341.86M | 372.79M | 371.51M |
| Operating Income | -195.17M | -208.15M | -341.66M | -372.59M | -369.77M |
| Income Before Tax | -155.08M | -163.69M | 1.72B | 1.69B | 1.64B |
| Income Tax Expenses | 2.00K | 2.00K | 2.00K | 2.00K | -2.00K |
| Earnings from Continuing Operations | -155.09 | -163.69 | 1.72K | 1.69K | 1.64K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -155.09M | -163.69M | 1.72B | 1.69B | 1.64B |
| EBIT | -195.17M | -208.15M | -341.66M | -372.59M | -369.77M |
| EBITDA | -192.56M | -205.37M | -339.06M | -370.30M | -367.88M |
| EPS Basic | -10.02 | -10.58 | 118.37 | 115.39 | 111.57 |
| Normalized Basic EPS | -7.93 | -8.28 | -14.11 | -15.96 | -16.69 |
| EPS Diluted | -10.03 | -10.59 | 116.74 | 113.77 | 109.95 |
| Normalized Diluted EPS | -7.93 | -8.28 | -14.02 | -15.88 | -16.60 |
| Average Basic Shares Outstanding | 61.88M | 61.87M | 61.02M | 59.19M | 57.26M |
| Average Diluted Shares Outstanding | 61.88M | 61.87M | 61.21M | 59.38M | 57.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |